At the news
? BULLISHIMPACT 7/10 6-K filed Jun 1, 2026 at 08:02 ET
Immatics N.V. filed a 6-K on June 1, 2026, reporting updated Phase 1 clinical data for three pipeline candidates presented at ASCO 2026: anzu-cel (IMA203) PRAME cell therapy in advanced melanoma showed 56% cORR, 14.6-month mDOR, 6.1-month mPFS, and 16.2-month mOS; IMA203CD8 PRAME cell therapy in gynecologic cancers showed 63% ORR (50% cORR) at clinically relevant doses with 4 complete responses; and IMA401 MAGEA4/8 bispecific in head and neck cancer showed 29% cORR and 8.8-month mDOR at RP2D. The filing also announced initiation of the IMA401/IMA402 combination cohort in sqNSCLC. These data collectively reinforce the clinical potential of Immatics' PRAME franchise across multiple solid tumor indications.
- Anzu-cel in advanced melanoma (n=33): 56% cORR, 14.6-month mDOR, 6.1-month mPFS, 16.2-month mOS; 42% of patients had deep responses (≥50% tumor reduction) with mPFS of 15.9 months
- IMA203CD8 in gynecologic cancers at clinically relevant doses (n=19): 63% ORR, 50% cORR, including 4 complete responses; 89% of confirmed responses ongoing with longest at 12 months
- IMA203CD8 in synovial sarcoma (n=12): 67% ORR, 64% cORR, including 1 complete response; mDOR 14.8 months at 31-month median follow-up
- IMA401 in head and neck cancer at RP2D (n=14): 29% cORR, 64% DCR, 8.8-month mDOR; 12-month OS rate 63%, 6-month PFS rate 43%
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access